Clinical Trials Directory

This study wants to see if a medicine called minoxidil can help people heal better after breast reconstruction surgery. Minoxidil is already approved by the FDA and may work by helping more blood flow to the skin. Everyone in the study will get two solutions before surgery. One solution has the medicine and the other does not. One will be put on one breast and the other on the other breast. Neither the patient nor the doctor will know which is which. The solutions will be used every day for two weeks before surgery. After surgery, the study team will check how well the healing went to see if the medicine made a difference.

We are doing this study to find out if adding a drug called enasidenib (the study drug) to the standard treatment for myelodysplastic syndrome (MDS) can improve the likelihood of achieving complete remission. The study drug is approved for acute myeloid leukemia (AML), but is not approved for the treatment of MDS.

In this study, people will be placed into treatment groups by a computer. They will be assigned by chance to receive either the usual treatment or a treatment that includes a study medicine called venetoclax. The usual treatment includes cancer medicines called gemtuzumab ozogamicin, cytarabine, and daunorubicin. The study treatment includes venetoclax along with cytarabine and daunorubicin. Researchers want to compare these treatment options to see which works better and how safe they are for people with this type of leukemia.

We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.

The purpose of this study is to better understand how prenatal maternal health, such as higher body mass, and well-being, such as mental health, are related to early child development. We are especially interested in identifying the factors that influence young children's ability to regulate their emotions. We hope that any new information we learn from this study could benefit young children in the years to come. El propósito de este estudio es comprender mejor cómo la salud prenatal de la madre, como una mayor masa corporal, y el bienestar, como la salud mental, están relacionados con el desarrollo tempano de los niños. Estamos especialmente interesados en identificar los factores que influyen en la capacidad de los niños pequeños para regular sus emociones. Esperamos que cualquier información nueva que obtengamos de este estudio pueda beneficiar a los niños pequeños en los años venideros.

Before joining the study, adults will be screened, that lasts up to one month. During this time, they will sign a consent form, share their medical history and medicines, have exams, heart tests, lab tests, imaging, and sometimes a tumor biopsy and a test for a gene change called PIK3CA. If eligible and want to continue, they will join either Cohort 5 or Cohort 6. A computer may choose the group by chance, or they may be placed in a group directly if only one is open. Some groups may require extra biopsies. Each person will sign a new consent for the treatment they are given. In Cohort 5, people who are pre diabetic may take a medicine like empagliflozin or metformin XR to help manage blood sugar. They will also take inavolisib with fulvestrant, and sometimes palbociclib. The first treatment cycle is a longer, then the rest last 28 days each. In Cohort 6, each 28 day cycle includes inavolisib taken by mouth once a day, atirmociclib taken by mouth two times a day, and fulvestrant given as a shot.

We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2-positive with mFOLFOX6 alone or combined with bevacizumab.